Search

Displaying results 2801 - 2810 of 4301 in total
  1. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  2. Drug

    Aminohippuric acid

    go.drugbank.com/drugs/DB00345
    ApprovedInvestigationalWithdrawn

    The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

  3. Drug

    Sodium lauryl sulfate

    go.drugbank.com/drugs/DB00815
    Approved

    Sodium Lauryl Sulfate (SLS) is an anionic surfactant naturally derived from coconut and/or palm kernel oil. It usually consists of a mixture of sodium alkyl sulfates, mainly the lauryl. SLS lowers surface tension of aqueous solutions and...

  4. Drug

    Desoximetasone

    go.drugbank.com/drugs/DB00547
    Approved

    A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.

  5. Drug

    Sipagladenant

    go.drugbank.com/drugs/DB17080
    Investigational

    KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822]

  6. Drug

    5-fluorotryptophan

    go.drugbank.com/drugs/DB03314
    Experimental

    5-fluorotryptophan can be used as substrate analogue to study enzyme mechanisms by NMR spectroscopy.

  7. Drug

    Atinumab

    go.drugbank.com/drugs/DB17923
    Investigational

    ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.

  8. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  9. Drug

    Cat dander extract

    go.drugbank.com/drugs/DB13904
    Approved

    An allergic reaction to cats is induced by the presence of antigen-specific IgE antibodies that are bound to specific receptors on mast cells and basophils.

  10. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.